NCT03653546 2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3 Completed
Clinical Trials
13 trialsNCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT02929693 2019-04-11
Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma
Shanghai University of Traditional Chinese Medicine
Phase 3 Unknown
NCT00206492 2017-08-01
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
Baylor Breast Care Center
Phase 2 Terminated
NCT00519077 2016-07-01
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
University of Chicago
Phase 2 Completed
NCT00588445 2016-01-22
Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00177242 2016-01-18
Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma
University of Pittsburgh
Phase 2 Completed
NCT01039948 2015-04-08
A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer
AVEO Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00034879 2013-01-04
Iressa Expanded Access Program (EAP)
AstraZeneca
Phase 3 Completed
NCT00189358 2010-07-20
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
AGO Study Group
Phase 2 Completed
NCT00127829 2009-04-23
AGUS
AstraZeneca
Phase 1 Completed
NCT00635973 2009-04-22
Open-Label Extension of Other SZ1839 (Iressa) Trials
AstraZeneca
Phase 3 Completed
NCT00135135 2008-06-03
Therapy for Children With Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed